The chemotherapy protocol for dogs varies depending on the type and stage of the tumor. Here’s a summary of the key information every pet owner should know.



| Item | Main drugs | Administration cycle | Main indications |
|---|---|---|---|
| High-dose conventional therapy | Vincristine, Cyclophosphamide | Once-weekly intravenous injection, repeated over several weeks | Lymphoma, leukemia |
| Metronomic therapy | Cyclophosphamide, Piroxicam | Low-dose daily administration, long-term continuation | Suppression of minimal residual/metastatic disease, nasal tumors |
| Customized drug therapy | Carboplatin, Doxorubicin | Approximately every 3 weeks, repeated several times | Mammary tumors, osteosarcoma |
The veterinarian selects based on the tumor type and individual condition.

Signs That Require an Immediate Vet Visit
If your pet loses its appetite completely and hasn’t eaten for more than 24 hours, or if you notice persistent vomiting or diarrhea, fever, or difficulty breathing, contact your veterinarian immediately. These could be signs of a serious adverse reaction.



A veterinarian who majored in veterinary medicine at Khon Kaen University, Thailand, and completed the IVSA program at North Carolina State University in the United States. Drawing on clinical experience at animal hospitals, he works in the pet healthcare field and is dedicated to building a digital care environment that connects pet parents with veterinarians.
Share
[1] Adamo, M., Dickie, L. and Ruhl, J. (2018) SEER Program Coding and Staging Manual 2018. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, Maryland.
[2] Lien, K., Georgsdottir, S., Sivanathan, L., Chan, K. and Emmenegger, U. (2013) Low-dose metronomic chemotherapy: a systematic literature analysis. European Journal of Cancer 49(16), 3387–3395.
[3] London, C.A., Gardner, H.L., Mathie, R. et al. (2008) Pharmacogenomic-driven chemotherapy in veterinary oncology: current status and future directions. Veterinary and Comparative Oncology 6(3), 145–157.